A juvenile ALS-like phenotype dramatically improved after high-dose riboflavin treatment.
Christophe CarreauTimothée LengletIsabelle MosnierGhizlene LahlouGuillaume FargeotNicolas WeissSophie DemeretFrançois SalachasAlice Veauville-MerlliéCécile AcquavivaYann NadjarPublished in: Annals of clinical and translational neurology (2020)
Riboflavin transporter deficiency (RTD) was recently characterized as a cause of genetic recessive childhood-onset motor neuron disease (MND) with hearing loss, formerly described as Brown-Vialetto-Van-Lear syndrome. We describe a 18-year-old woman with probable RTD mimicking juvenile Amyotrophic Lateral Sclerosis (ALS) who presented with an inaugural respiratory failure and moderate distal four limbs weakness. Only one heterozygous SLC52A3 mutation was detected, but presence of a sub-clinical auditory neuropathy and dramatic improvement under high dose riboflavin argued for a RTD. As RTD probably has a larger phenotypic spectrum than expected, a high dose riboflavin trial should be discussed in young-onset MND.
Keyphrases
- high dose
- amyotrophic lateral sclerosis
- respiratory failure
- hearing loss
- stem cell transplantation
- low dose
- extracorporeal membrane oxygenation
- clinical trial
- mechanical ventilation
- study protocol
- early onset
- working memory
- minimally invasive
- intellectual disability
- gene expression
- autism spectrum disorder
- double blind